Please assess the completion status of the following clinical trial:

Trial Title: VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~A volunteer must have met all of the following criteria:~* Age 18 to 50 years~* Available for clinical follow-up through 36 weeks after randomization~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process~* Able and willing to complete the informed consent process~* Willing to donate blood for sample storage to be used for future research~* In good general health, without clinically significant medical history, and has satisfactorily completed screening~* Physical examination and laboratory results without clinically significant findings within the 28 days prior to randomization~Laboratory Criteria within 28 days prior to randomization:~* Hemoglobin within institutional normal range or accompanied by Principal Investigator (PI) or designee approval~* White blood cell (WBC) and differential either within institutional normal range or accompanied by PI or designee approval~* Total lymphocyte count: ≥800 cells/mm3~* Platelets: 125,000-500,000/mm3~* Alanine aminotransferase (ALT): ≤ 1.25 x upper limit of normal range~* Serum creatinine: ≤1.1 x upper limit of normal~* Negative for HIV infection by an FDA-approved method of detection~Criteria applicable to women of childbearing potential:~* Negative beta-human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of randomization before receiving the study product~* Agrees to use an effective method of birth control, if sexually active, from at least 21 days prior to randomization through the last study visit.~Exclusion Criteria:~A volunteer was excluded if one or more of the following conditions applied:~Female-Specific Criteria~• Breast-feeding or planning to become pregnant while participating in the study~Volunteer received any of the following:~* More than 10 days of systemic immunosuppressive medications or cytotoxic medications within the 4 weeks prior to randomization or any within the 14 days prior to randomization~* Blood products within 16 weeks prior to randomization~* Immunoglobulin within 8 weeks prior to randomization~* Prior vaccinations with an investigational alphavirus vaccine~* Investigational research agents within 4 weeks prior to randomization or planning to receive investigational products while on study~* Live attenuated vaccines within 4 weeks prior to randomization~* Inactivated vaccines within 2 weeks prior initial study vaccine administration unless approved by the PI~* Current anti-tuberculosis (TB) prophylaxis or therapy~Volunteer has a history of any of the following clinically significant conditions:~* A history of confirmed or suspected viral encephalitis infection~* Serious reactions to vaccines that preclude receipt of study vaccinations as determined by the investigator~* Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema~* Asthma that is not well controlled~* Diabetes mellitus (type I or type II) with the exception of gestational diabetes~* Thyroid disease that is not well controlled~* Hypertension that is not well controlled~* Evidence of autoimmune disease or immunodeficiency~* Idiopathic urticaria within the last year~* Malignancy that is active or history of malignancy that is likely to recur during the study~* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with intramuscular (IM) product administration or blood draws~* Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures or treatment for a seizure disorder within the last 3 years~* Asplenia, functional asplenia or any condition resulting in absence or removal of the spleen~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within 5 years prior to randomization, a history of suicide plan or attempt~* Any other chronic or clinically significant medical, psychiatric or social condition that, in the judgement of the investigator is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: 6 mcg WEVEE vaccine (Type: EXPERIMENTAL): 6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
- Group 2: 6 mcg WEVEE vaccine + alum (Type: EXPERIMENTAL): 6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
- Group 3: 30 mcg WEVEE vaccine (Type: EXPERIMENTAL): 30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
- Group 4: 30 mcg WEVEE vaccine + alum (Type: EXPERIMENTAL): 30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
- Group 5: 60 mcg WEVEE vaccine (Type: EXPERIMENTAL): 60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
- Group 6: 60 mcg WEVEE vaccine + alum (Type: EXPERIMENTAL): 60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8

Based on this trial design, predict the completion outcome and termination type (if applicable).